About this medicine

Treatment includes educational, psychological and social support where appropriate. A specialist establishes the diagnosis and starts medication.

What is this medicine used for?

The checked UK licence covers children aged six and over after inadequate methylphenidate response, and adults with childhood ADHD symptoms. It does not license binge-eating treatment. NICE lists lisdexamfetamine or methylphenidate as first-line adult medication options; local pathways differ.

For children, this product’s licensed age range is separate from its place in the NICE treatment sequence. The ADHD article explains when this option may be considered after assessment, environmental changes and review of earlier treatment. Follow the exact formulation’s prescribing information and the agreed specialist monitoring plan.

Which warning signs need help?

Seek urgent help for chest pain, collapse, seizures, severe allergic symptoms, mania or hallucinations. Dependence, misuse and diversion are recognised risks: store securely and never share. For a life-threatening emergency use local emergency services. UK product warnings are not FDA boxed-warning designations.

How do I take it safely?

The label starts at 30 mg each morning, or 20 mg when a lower start is appropriate, with 10–20 mg increases about weekly and a maximum of 70 mg/day. Severe kidney impairment has a lower limit. Capsule contents may be mixed with yoghurt, water or orange juice and consumed immediately in full. Do not split doses.

The SmPC limits severe renal impairment to 50 mg/day and calls for further consideration in dialysis. This is separate from the usual 70 mg maximum; the medicine is not removed by dialysis.

What side effects should I know about?

Reduced appetite, insomnia, dry mouth and headache are very common. Anxiety, irritability, weight loss and stomach symptoms also occur.

Who needs extra care with this medicine?

Contraindications include specified cardiovascular disease, moderate/severe hypertension, hyperthyroidism, glaucoma and MAOI use within the previous 14 days. The complete label must be checked.

Can it affect my other medicines?

MAOIs can cause dangerous interactions. Check antidepressants, cough/cold remedies and medicines that alter urine acidity with a pharmacist.

SSRIs and SNRIs can add serotonin-syndrome risk. Fever, agitation, sweating and muscle twitching require urgent assessment rather than assuming a normal stimulant effect.

What check-ups will I need?

NICE recommends pulse and blood pressure checks after dose changes and every six months. Review weight, children’s growth, sleep, mental state and continuing benefit.

Before treatment, record cardiovascular history, family history of sudden death, medicines and psychiatric symptoms. Review new or worsening psychiatric symptoms at dose changes and visits. Continued treatment beyond a year needs at least yearly benefit review; any trial off medication is planned professionally.

What about pregnancy, breastfeeding and age?

Use during pregnancy requires explicit medical advice. The checked leaflet advises against breastfeeding while taking Elvanse. It is not indicated below age six.

Available observational amfetamine data do not suggest increased overall congenital-malformation risk, but other studies suggest pre-eclampsia and premature birth risks. Newborn withdrawal is possible. This evidence does not establish zero risk or replace individual specialist advice.

What if I miss a dose or want to stop?

Skip a forgotten dose until the next day; avoid afternoon catch-up doses and never double. Discuss stopping with the prescriber.

How does it work?

Lisdexamfetamine is a prodrug, meaning the body must convert it into another substance before its main medicine effect occurs. That substance is dexamfetamine, which changes the handling of dopamine and noradrenaline, chemical messengers used by nerve cells. Researchers understand this conversion and these messenger effects, but not every step connecting them with improvement in symptoms.

How Brain Cells Communicate

Nerve cells release dopamine and norepinephrine, also called noradrenaline, into the small spaces between cells. These chemical messengers, or neurotransmitters, influence receiving cells before being removed or taken back up. Transporters are proteins that return messengers into nerve cells; that return is called reuptake. Release and reuptake together help control when and where a chemical message is available.

What is known: Cells regulate both the release and the return of these messengers.

What remains uncertain: These processes do not establish a simple chemical shortage in a person with attention-deficit/hyperactivity disorder (ADHD).

Dopamine recycling

A transporter across a membrane, with the sending-cell interior above and released messenger outside below. The uptake direction is upward. Dopamine: The messenger is shown outside the sending cell. DAT: This transporter returns dopamine from outside into the sending cell. Return into the cell: The arrow shows transport direction, without a measured rate.
  1. Dopamine

    The messenger is shown outside the sending cell.

  2. DAT

    This transporter returns dopamine from outside into the sending cell.

  3. Return into the cell

    The arrow shows transport direction, without a measured rate.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

DAT participates in returning released dopamine into a nerve cell.

Norepinephrine recycling

A transporter across a membrane, with the sending-cell interior above and released messenger outside below. The uptake direction is upward. Norepinephrine: The messenger is shown outside the sending cell. NET: This transporter returns norepinephrine from outside into the sending cell. Return into the cell: The arrow shows transport direction, without a measured rate.
  1. Norepinephrine

    The messenger is shown outside the sending cell.

  2. NET

    This transporter returns norepinephrine from outside into the sending cell.

  3. Return into the cell

    The arrow shows transport direction, without a measured rate.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

NET participates in returning norepinephrine through its own transport system.

Cells regulate both the release and the return of these messengers. Simplified illustration of the process; individual responses vary.
About this illustration

Nerve cell releases → Dopamine + norepinephrine → Transporters recycle. These processes do not establish a simple chemical shortage in a person with attention-deficit/hyperactivity disorder (ADHD).

Release and reuptake are parts of messenger signaling, not a measured shortage.

Qualitative model · no scale, rate, dose or binding pose

How the Medication Changes Signaling

After lisdexamfetamine enters the bloodstream, red blood cells do most of the work of converting it into dexamfetamine, called dextroamphetamine in US sources, and lysine. Dexamfetamine is the active stimulant, a medicine that increases activity in certain brain and body signalling systems. It reduces dopamine and noradrenaline reuptake and increases their release, changing how much is available outside nerve cells. The original, intact lisdexamfetamine molecule does not bind to those reuptake sites in laboratory studies.

What is known: Conversion in the blood supplies the substance responsible for the main stimulant action.

What remains uncertain: Being converted first does not remove the risks of taking too much, physical dependence, in which the body adapts to regular use, or effects on the heart and blood vessels.

How the process works

  1. Lisdexamfetamine
  2. Blood conversion
  3. Dextroamphetamine
Conversion in the blood supplies the substance responsible for the main stimulant action. Simplified illustration of the process; individual responses vary.
About this illustration

Lisdexamfetamine → Blood conversion → Dextroamphetamine. Being converted first does not remove the risks of taking too much, physical dependence, in which the body adapts to regular use, or effects on the heart and blood vessels.

Red-cell conversion produces the active stimulant and lysine; the arrow does not encode a rate.

Qualitative model · no scale, rate, dose or binding pose

A Closer Look at the Molecular Level

Lisdexamfetamine links dextroamphetamine to lysine, an amino acid, one of the small building blocks used to make proteins. Hydrolysis is the chemical reaction that uses water to split this connection and release the active medicine. Knowing which bond is split explains the conversion, while the actions on messenger release and reuptake describe what the resulting medicine does. Neither by itself explains all the changes in attention or behavior that may develop during treatment.

What is known: Splitting the prodrug produces active dextroamphetamine and lysine.

What remains uncertain: Understanding the chemistry does not determine the degree or timing of individual benefit.

How the process works

  1. Prodrug bond is split
  2. Active messenger effects
  3. Clinical response varies
Splitting the prodrug produces active dextroamphetamine and lysine. Simplified illustration of the process; individual responses vary.
About this illustration

Prodrug bond is split → Active messenger effects → Clinical response varies. Understanding the chemistry does not determine the degree or timing of individual benefit.

Chemical conversion, signaling action and clinical benefit are separate levels of explanation.

Qualitative model · no scale, rate, dose or binding pose

How does it affect my body?

Appetite, sleep, weight, pulse and blood pressure can change. Treatment benefit should be considered alongside these effects.

How does my body process it?

Conversion to dexamfetamine provides prolonged action. Severe kidney impairment reduces clearance and lowers the label’s maximum dose.

How do treatment options differ?

Lisdexamfetamine and methylphenidate are distinct medicines; capsule milligrams are not equivalent doses. A US brand alias does not prove UK product availability.

A closer look at the science

Red blood cells mainly perform conversion. Dexamfetamine increases monoamine release and reduces reuptake; the precise therapeutic pathway in ADHD remains incompletely established.

Lisdexamfetamine dimesylate contains lisdexamfetamine with two mesylate components. This is the prodrug, before conversion to dextroamphetamine.

Chemical formula: C15H25N3O · (CH4O3S)2

C, H, N, O and S denote carbon, hydrogen, nitrogen, oxygen and sulfur. The dot and subscript 2 identify the two mesylate components of the salt. They are not two additional stimulant doses.

Official label structure of lisdexamfetamine dimesylate with two methanesulfonate components.
Structure reproduced from the selected DailyMed label, section 11. Lines show connectivity; this is not a protein-bound pose.

How was this medicine developed?

The 30 mg UK authorisation dates to February 2013. Takeda’s September 2025 communication describes combined Elvanse labelling for children and adults and withdrawal of the separate Elvanse Adult pack.

Sources and References

  1. Elvanse 30 mg capsules — UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  2. Elvanse 20–70 mg capsules — patient leaflet

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  3. Lisdexamfetamine for adult services — local shared-care protocol

    Scope: England, Nottinghamshire local shared-care protocol.

  4. Attention deficit hyperactivity disorder: diagnosis and management (NG87), recommendations

    Scope: NICE guidance for England; application in other UK nations determined separately.

  5. Elvanse: one dose range for children, adolescents and adults

    Scope: UK manufacturer product communication, hosted by an English local NHS committee.

  6. Vyvanse: current product prescribing information
  7. ADHD: full recommendations PDF

    Scope: United Kingdom; NICE recommendations require attention to national implementation and local pathways.

  8. Vyvanse: FDA prescribing information, April 2026
  9. Schizophrenia
  10. NIMH: Understanding psychosis

Shared scientific background. Some references are US product pharmacology or international chemical records; UK product details and prescribing information are verified separately.

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top